People: StemCells Inc (STEM.OQ)

STEM.OQ on NASDAQ Stock Exchange Capital Market

2.05USD
11 Jul 2014
Price Change (% chg)

$0.03 (+1.49%)
Prev Close
$2.02
Open
$2.03
Day's High
$2.06
Day's Low
$2.03
Volume
151,671
Avg. Vol
285,424
52-wk High
$2.42
52-wk Low
$1.16

Search Stocks

Summary

Name Age Since Current Position

John Schwartz

79 1998 Independent Chairman of the Board

Martin McGlynn

67 2001 President, Chief Executive Officer, Director

Gregory Schiffman

2014 Chief Financial Officer, Executive Vice President - Finance

Ann Tsukamoto

61 2013 Executive Vice President - Scientific and Strategic Alliances

Kenneth Stratton

45 2007 General Counsel

Alan Trounson

2014 Director

Irving Weissman

73 1997 Director

Eric Bjerkholt

54 2004 Independent Director

R. Scott Greer

55 2010 Independent Director

Ricardo Levy

68 2001 Independent Director

Biographies

Name Description

John Schwartz

Dr. John J. Schwartz, Ph.D., is Independent Chairman of the Board of StemCells Inc. Dr. Schwartz has over 40 years of business and legal experience, including several years spent in the 1990s as President and Chief Executive Officer of Systemix, Inc., a cell-based therapeutics company which was acquired by Novartis in 1997. Before joining Systemix as its Senior Vice President and General Counsel in 1993, Dr. Schwartz served as the Vice President and General Counsel of Stanford University. He currently runs a registered investment advisor firm called Quantum Strategies Management Company.

Martin McGlynn

Mr. Martin M. McGlynn is President, Chief Executive Officer, Director of StemCells Inc. He has held management positions of increasing responsibility in several countries for more than 30 years. Prior to joining our company, Mr. McGlynn was President and Chief Executive Officer of Pharmadigm, Inc., a privately held company in the fields of inflammation and genetic immunization. Prior to this, he was President and General Manager of Abbott Canada Ltd. and President of Anaquest, Inc., a company focused on anesthesia and acute care pharmaceuticals.

Gregory Schiffman

Mr. Gregory T. Schiffman has been appointed as Chief Financial Officer, Executive Vice President - Finance of StemCells, Inc., effective January 1, 2014. Mr. Schiffman is a seasoned executive in the healthcare industry, with over fifteen years of experience leading the financial operations and strategy of global publicly-traded companies such as Affymetrix and Applied Biosystems. Most recently, Mr. Schiffman was Executive Vice President and CFO of Dendreon Corporation since 2007, where he had primary responsibility for capital raising, financial reporting and controls, information technology, and investor relations. In April 2010, Dendreon secured marketing authorization from the U.S. Food and Drug Administration (FDA) for Provenge®, the world's first cell–based autologous immunotherapy for prostate cancer, followed by European Commission authorization in September 2013. Before entering the healthcare field, Mr. Schiffman held roles of increasing responsibility within Hewlett Packard, where he served as controller of its European P.C. manufacturing and distribution operations in Grenoble, France, and as manufacturing manager and controller of its Netmetrix Division. Mr. Schiffman holds a bachelor's degree in accounting from De Paul University and an MBA from the Kellogg Graduate School of Management at Northwestern University.

Ann Tsukamoto

Dr. Ann Tsukamoto, Ph.D., is Executive Vice President - Scientific and Strategic Alliances of StemCells Inc. She was appointed Vice President, Scientific Operations in June 1998; Vice President, Research and Development in February 2002; Chief Operating Officer in November 2006; and Executive Vice President, Research and Development, in October 2008. In June 2013, Dr. Tsukamoto was appointed Executive Vice President, Scientific and Strategic Alliances, with responsibility for developing the Company’s alliances with research institutions, corporations, government agencies, and disease foundations. Dr. Tsukamoto is married to one of our outside directors.

Kenneth Stratton

Mr. Kenneth Stratton, J.D., is General Counsel of StemCells Inc. In March 2008, he assumed responsibility for the Human Resources function. Prior to joining StemCells, Mr. Stratton served as Deputy General Counsel for Threshold Pharmaceuticals and as Senior Legal Counsel for Medtronic, Inc.’s Vascular business unit.

Alan Trounson

Dr. Alan O. Trounson, Ph.D. is Director of the Company. Dr. Trounson has been the recipient of over 30 awards and distinctions for his scientific work, including pioneering work in the fields of in-vitro fertilization and stem cells. As part of his academic research, Dr. Trounson pioneered a new stem cell biology approach for the treatment of a broad range of diseases and injuries, which was awarded the first ever Australian Center of Excellence in Biotechnology grant worth $110 million dollars. Dr. Trounson's previous academic positions include Scientific Director of Monash IVF Pty Ltd., Personal Chair in Stem Cell Science and Director of the Monash Immunology and Stem Cell Laboratories, Deputy Director/Director of the Monash Institute of Reproduction and Development, Director of the Centre of Early Human Development, Facility of Medicine, and Personal Chair of Obstetrics and Gynaecology-Pediatrics at Monash University in Melbourne, Australia. He has founded a number of companies including Infertility Medical Center Pty Ltd./Monash IVF Pty Ltd., IVF Australia Corp/IntegraMed Corp (US), Sydney IVF Pty Ltd./Genea Pty Ltd., Maccine Pte Ltd and the Australian Stem Cell Center Ltd. He established two foundations, the Low Cost IVF Foundation for the treatment of infertile women in Africa and for the treatment of patients with HIV, to avoid vertical transmission to children and the Friends of Low Cost IVF (US). He is returning to Melbourne to continue to support international biotechnology in regenerative medicine.

Irving Weissman

Dr. Irving L. Weissman, M.D., is Director of StemCells Inc. Dr. Weissman has been a leader in the stem cell field for over 20 years. He is a professor at Stanford University and serves as the director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. He co-founded Systemix in 1988 and Cellerant Therapeutics, Inc., a hematopoietic stem cell development company, in 2001. He is a member of several scientific advisory boards and national science institutes, including the National Academy of Science, the American Academy of Arts and Science, and the Institute of Medicine of the National Academy of Sciences.

Eric Bjerkholt

Mr. Eric H. Bjerkholt is Independent Director of StemCells Inc. Mr. Bjerkholt is a financial expert and currently serves as the Executive Vice President and Chief Financial Officer of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company. His business experience spans more than 20 years, during which time he founded a nutraceutical company and worked as an investment banker. Mr. Bjerkholt currently serves on the board of directors of Round Table Pizza.

R. Scott Greer

Mr. R. Scott Greer is Independent Director of StemCells Inc. He is a financial expert with over 25 years of experience in the life sciences industry. He was founder, CEO and Chairman of Abgenix, Inc., a biotechnology company he took public in 1998 and then sold to Amgen in 2006. Mr. Greer currently serves as Chairman of Ablexis, a development stage biotechnology company, and is also on the board of Nektar Therapeutics.

Ricardo Levy

Dr. Ricardo B. Levy, Ph.D., is Independent Director of StemCells Inc. Dr. Levy has over 30 years of experience leading technology companies in both North and South America. In 1974, he cofounded Catalytica, Inc., a manufacturing technology and energy systems company, and served as CEO from 1991 until the company was sold in 2000. Dr. Levy currently serves as director of Accerlys Inc. (formerly Pharmacopeia, Inc.) and NovoDynamics, Inc.

Basic Compensation

Options Compensation

Search Stocks